NCT06163040 - A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

Elotuzumab in combination with pomalidomide and dexamethasone

Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)

DRUG

Elotuzumab in combination with lenalidomide and dexamethasone

Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)

Trial Locations (4)

613

Chang Gung Memorial Hospital- Chiayi, Chiayi City

40447

China Medical University Hospital, Taoyuan

80756

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

100229

National Taiwan University Hospital, Taipei